The system will be going down for regular maintenance. Please save your work and logout.
Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies
Language
en
Chapitre d'ouvrage
This item was published in
Economic Dimensions of Personalized and Precision Medicine. 2019p. 305-334
University of Chicago Press
Origin
Hal imported